2024's 'Biggest Loses' That Could See Reversal in 2025

Seeking AlphaDec 23 23:00

Express News | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of Aro-Inhbe for the Treatment of Obesity

BreakingsDec 23 20:30

Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,486, According to a Recent SEC Filing

MT NewswiresDec 23 17:03

H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80

Futu NewsDec 21 03:31 · Ratings

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow JonesDec 21 00:12 · Ratings

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BusinesswireDec 20 05:59